Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies.

Details

Ressource 1Download: 32003460_BIB_5DEC7758E430.pdf (773.80 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_5DEC7758E430
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies.
Journal
International journal of cancer
Author(s)
Trickey A., May M.T., Gill M.J., Grabar S., Vehreschild J., Wit FWNM, Bonnet F., Cavassini M., Abgrall S., Berenguer J., Wyen C., Reiss P., Grabmeier-Pfistershammer K., Guest J.L., Shepherd L., Teira R., d'Arminio Monforte A., Del Amo J., Justice A., Costagliola D., Sterne JAC
ISSN
1097-0215 (Electronic)
ISSN-L
0020-7136
Publication state
Published
Issued date
01/06/2020
Peer-reviewed
Oui
Volume
146
Number
11
Pages
3134-3146
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
People living with HIV (PLHIV) are more likely than the general population to develop AIDS-defining malignancies (ADMs) and several non-ADMs (NADMs). Information is lacking on survival outcomes and cause-specific mortality after cancer diagnosis among PLHIV. We investigated causes of death within 5 years of cancer diagnosis in PLHIV enrolled in European and North American HIV cohorts starting antiretroviral therapy (ART) 1996-2015, aged ≥16 years, and subsequently diagnosed with cancer. Cancers were grouped: ADMs, viral NADMs and nonviral NADMs. We calculated cause-specific mortality rates (MR) after diagnosis of specific cancers and compared 5-year survival with the UK and France general populations. Among 83,856 PLHIV there were 4,436 cancer diagnoses. Of 603 deaths after ADM diagnosis, 292 (48%) were due to an ADM. There were 467/847 (55%) and 74/189 (39%) deaths that were due to an NADM after nonviral and viral NADM diagnoses, respectively. MR were higher for diagnoses between 1996 and 2005 versus 2006-2015: ADMs 102 (95% CI 92-113) per 1,000 years versus 88 (78-100), viral NADMs 134 (106-169) versus 111 (93-133) and nonviral NADMs 264 (232-300) versus 226 (206-248). Estimated 5-year survival for PLHIV diagnosed with liver (29% [19-39%]), lung (18% [13-23%]) and cervical (75% [63-84%]) cancer was similar to general populations. Survival after Hodgkin's lymphoma diagnosis was lower in PLHIV (75% [67-81%]). Among ART-treated PLHIV diagnosed with cancer, MR and causes of death varied by cancer type, with mortality highest for liver and lung cancers. Deaths within 5 years of NADM diagnoses were more likely to be from cancer than AIDS.
Keywords
ADM, NADM, PLHIV, cancer, cohort, mortality
Pubmed
Web of science
Open Access
Yes
Create date
06/02/2020 17:50
Last modification date
23/11/2022 7:11
Usage data